New Glance at the Role of TM6SF2 in Lipid Metabolism and Liver Cancer
Xiaoxiao Jiang, Hui Qian, Wen‐Xing Ding – 6 April 2021
HBV/Pregenomic RNA Increases the Stemness and Promotes the Development of HBV‐Related HCC Through Reciprocal Regulation With Insulin‐Like Growth Factor 2 mRNA‐Binding Protein 3
Wen‐bin Ding, Meng‐chao Wang, Jian Yu, Gang Huang, Da‐peng Sun, Lei Liu, Jia‐ning Zhang, Yuan Yang, Hui Liu, Wei‐ping Zhou, Fu Yang, Sheng‐xian Yuan – 6 April 2021
Therapeutic Potential of G Protein‐Coupled Receptors Against Nonalcoholic Steatohepatitis
Dating Sun, Xia Yang, Bin Wu, Xiao‐Jing Zhang, Hongliang Li, Zhi‐Gang She – 6 April 2021
Perivenous Stellate Cells Are the Main Source of Myofibroblasts and Cancer‐Associated Fibroblasts Formed After Chronic Liver Injuries
Shan‐Shan Wang, Xinyu Thomas Tang, Minghui Lin, Jia Yuan, Yi Jacky Peng, Xiujuan Yin, GuoGuo Shang, Gaoxiang Ge, Zhenggang Ren, Bo O. Zhou – 4 April 2021
Loss‐of‐Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia
Yi Niu, Ziyou Lin, Arabella Wan, Lei Sun, Shijia Yan, Heng Liang, Siyue Zhan, Dongshi Chen, Xianzhang Bu, Peiqing Liu, Ceshi Chen, Weiling He, Xiongbin Lu, Guohui Wan – 3 April 2021
Cancer Risk in Patients With Biopsy‐Confirmed Nonalcoholic Fatty Liver Disease: A Population‐Based Cohort Study
Tracey G. Simon, Bjorn Roelstraete, Rajani Sharma, Hamed Khalili, Hannes Hagström, Jonas F. Ludvigsson – 2 April 2021
Mechanistic Rationales Guiding Combination Hepatocellular Carcinoma Therapies Involving Immune Checkpoint Inhibitors
Jacinth Wing‐Sum Cheu, Carmen Chak‐Lui Wong – 2 April 2021 – Hepatocellular carcinoma (HCC) is one of the deadliest cancers because of late symptom manifestation leading to delayed diagnosis, which limits patients with HCC in terms of receiving curative surgical treatment. There are only a few therapeutic options for patients with advanced HCC. The emergence of immune checkpoint inhibitors (ICIs) brings HCC treatment to a stage at which nivolumab, an anti–programmed cell death protein 1 monoclonal antibody, achieves a 20% response rate.
Heterozygosity of the Alpha 1‐Antitrypsin Pi*Z Allele and Risk of Liver Disease
Aaron Hakim, Matthew Moll, Dandi Qiao, Jiangyuan Liu, Jessica A. Lasky‐Su, Edwin K. Silverman, Silvia Vilarinho, Z. Gordon Jiang, Brian D. Hobbs, Michael H. Cho – 2 April 2021 – The serpin family A member 1 (SERPINA1) Z allele is present in approximately one in 25 individuals of European ancestry. Z allele homozygosity (Pi*ZZ) is the most common cause of alpha 1‐antitrypsin deficiency and is a proven risk factor for cirrhosis. We examined whether heterozygous Z allele (Pi*Z) carriers in United Kingdom (UK) Biobank, a population‐based cohort, are at increased risk of liver disease.
REPLY:
Yun Bin Lee, Juneyoung Lee – 1 April 2021
Impact of Sodium Glucose Cotransporter 2 Inhibitors on Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus
Enxiang Zhang, Yang Zhao, Hongbo Hu – 1 April 2021 – Sodium glucose cotransporter 2 (SGLT2), a type of membrane protein highly expressed in the kidney, can regulate plasma glucose through the glomerular filtration process by reabsorption from the kidney. SGLT2 inhibitors, which are newly developed oral antidiabetic drugs, can play a role in liver diseases by inhibiting SGLT2‐mediated renal glucose reabsorption and inducing glycosuria. Nonalcoholic fatty liver disease (NAFLD) is the most common type of liver disease, resulting in severe liver dysfunction.